People: Charles River Laboratories International Inc (CRL.N)

CRL.N on New York Stock Exchange

18 Oct 2019
Change (% chg)

$-1.79 (-1.32%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Bertolini, Robert 

Mr. Robert J. Bertolini CPA is an Independent Director of Charles River Laboratories International Inc. He President and Chief Financial Officer of Bausch & Lomb Incorporated from February 2013 to August 2013 (until its acquisition by Valeant Pharmaceuticals International, Inc.). Mr. Bertolini served as Executive Vice President and Chief Financial Officer at Schering-Plough Corp. from November 2003 until November 2009 (until its merger with Merck & Co) with responsibility for tax, accounting, and financial asset management. Prior to joining Schering-Plough, Mr. Bertolini spent 20 years at PricewaterhouseCoopers LLP, ultimately leading its global pharmaceutical industry practice. Mr. Bertolini also serves as a director of Bristol-Meyers Squibb Company and Idorsia, Ltd., a Swiss public company. He served as a director of Genzyme Corporation until its merger with Sanofi-Aventis in 2011 and of Actelion until it was acquired by Johnson & Johnson in June 2017. Mr. Bertolini has been a director since January 2011. Mr. Bertolini's qualifications to serve as a director include his industry and financial expertise. He has extensive experience in building world-class finance and information technology functions and in leading business development and strategy. Having joined Schering-Plough at a time when it was facing challenges across several areas, Mr. Bertolini was part of the team that turned Schering-Plough around and drove strategic decisions. He has had responsibility for key financial areas including tax, accounting, and financial asset management, and extensive experience in audit, financial controls and corporate governance. He has expertise in working with small and large health care companies on initial public offerings, licensing, and other strategic issues. As a result of his extensive background in public accounting and prior experience as a public company Chief Financial Officer, Mr. Bertolini qualifies as an "audit committee financial expert" under SEC guidelines.

Basic Compensation

Total Annual Compensation, USD 80,000
Restricted Stock Award, USD 215,049
Long-Term Incentive Plans, USD --
All Other, USD --
Fiscal Year Total, USD 295,049

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

James Foster


David Smith


David Johst


William Barbo


Birgit Girshick


George Milne

As Of  29 Dec 2018